公开(公告)号：US11230545B2

公开(公告)日：2022-01-25

申请号：US17367171

申请日：2021-07-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Hiroshi Banno ,  Hidekazu Tokuhara ,  Toshio Tanaka ,  Yasuyoshi Arikawa ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US10189785B2

公开(公告)日：2019-01-29

申请号：US15565891

申请日：2016-04-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasutomi Asano ,  Takuto Kojima ,  Osamu Kurasawa ,  Tzu-Tshin Wong ,  Yasuhiro Hirata ,  Naoki Iwamura ,  Bunnai Saito ,  Yuta Tanaka ,  Ryosuke Arai ,  Shinichi Imamura ,  Kazuko Yonemori ,  Yasufumi Miyamoto ,  Shuji Kitamura ,  Osamu Sano

IPC: C07D211/58 ,  C07D215/42 ,  C07D401/02 ,  C07D413/06 ,  C07D413/14 ,  A61K31/444 ,  A61K31/4709 ,  C07F9/6509 ,  C07D401/14 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/452 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/661 ,  A61K33/22 ,  C07D401/06 ,  C07D401/12 ,  C07D409/12 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07F5/02 ,  A61P3/00 ,  A61P35/00 ,  C07B59/00 ,  C07D405/06

Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

公开(公告)号：US20220089595A1

公开(公告)日：2022-03-24

申请号：US17528677

申请日：2021-11-17

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.

公开(公告)号：US10981934B2

公开(公告)日：2021-04-20

申请号：US16663601

申请日：2019-10-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Youichi Kawakita ,  Takuto Kojima ,  Noriyuki Nii ,  Yoshiteru Ito ,  Nobuki Sakauchi ,  Hiroshi Banno ,  Xin Liu ,  Koji Ono ,  Keisuke Imamura ,  Shinichi Imamura

IPC: A61K31/53 ,  C07D519/00 ,  A61K31/444 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/4985 ,  A61P35/00

Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].

公开(公告)号：US10577382B2

公开(公告)日：2020-03-03

申请号：US16094030

申请日：2017-04-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Youichi Kawakita ,  Takuto Kojima ,  Noriyuki Nii ,  Yoshiteru Ito ,  Nobuki Sakauchi ,  Hiroshi Banno ,  Xin Liu ,  Koji Ono ,  Keisuke Imamura ,  Shinichi Imamura

IPC: C07D519/00 ,  A61K31/53 ,  A61P35/00

Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein].

公开(公告)号：US10519110B2

公开(公告)日：2019-12-31

申请号：US16175144

申请日：2018-10-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasutomi Asano ,  Takuto Kojima ,  Osamu Kurasawa ,  Tzu-Tshin Wong ,  Yasuhiro Hirata ,  Naoki Iwamura ,  Bunnai Saito ,  Yuta Tanaka ,  Ryosuke Arai ,  Shinichi Imamura ,  Kazuko Yonemori ,  Yasufumi Miyamoto ,  Shuji Kitamura ,  Osamu Sano

IPC: C07D211/58 ,  C07F9/6509 ,  C07D401/14 ,  A61K31/437 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5355 ,  A61K31/661 ,  A61K33/22 ,  C07D215/42 ,  C07D401/06 ,  C07D401/12 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  C07D519/00 ,  C07F5/02 ,  A61P3/00 ,  A61P35/00 ,  C07B59/00 ,  C07D405/06 ,  C07D413/14

Abstract: The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

公开(公告)号：US10774083B2

公开(公告)日：2020-09-15

申请号：US16333296

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu Hirayama ,  Yasuhiro Hirata ,  Yusuke Tominari ,  Naoki Iwamura ,  Yusuke Sasaki ,  Moriteru Asano ,  Terufumi Takagi ,  Masanori Okaniwa ,  Shinichi Imamura

IPC: C07D401/04 ,  C07D401/14 ,  C07D473/28 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D473/40 ,  C07D519/00 ,  A61P35/00 ,  A61K31/506 ,  A61K31/444 ,  A61K31/4439 ,  C07D473/00 ,  C07D473/32 ,  A61K31/5377 ,  A61K31/501 ,  A61K31/52 ,  A61P43/00 ,  A61K31/437 ,  C12N9/99

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US09751885B2

公开(公告)日：2017-09-05

申请号：US14435085

申请日：2013-10-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Naoki Tomita ,  Daisuke Tomita ,  Yusuke Tominari ,  Shinichi Imamura ,  Shinji Morimoto ,  Takuto Kojima ,  Masashi Toyofuku ,  Yasushi Hattori ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D487/04 ,  C07C255/58 ,  C07C255/60 ,  C07D231/40 ,  C07C317/40 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  A61K45/06 ,  C07D309/14 ,  C07D319/18 ,  C07D413/12 ,  C07D241/12 ,  C07D417/12 ,  C07D261/14 ,  C07D207/12 ,  C07D285/135 ,  C07D211/58 ,  C07D295/135 ,  C07D213/40 ,  C07D207/46 ,  C07D213/36 ,  C07D223/12 ,  C07D231/38 ,  C07D241/18 ,  C07D265/36 ,  C07D277/38 ,  C07D333/20 ,  C07D405/12 ,  C07D471/04 ,  C07D513/04

CPC classification number: C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

公开(公告)号：US09682925B2

公开(公告)日：2017-06-20

申请号：US15005574

申请日：2016-01-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Naoki Tomita ,  Shigeo Kajii ,  Douglas Robert Cary ,  Daisuke Tomita ,  Shinichi Imamura ,  Ken Tsuchida ,  Satoru Matsuda ,  Ryujiro Hara

IPC: A61K31/167 ,  A61K31/36 ,  A61K31/366 ,  A61K31/40 ,  A61K31/402 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/451 ,  A61K31/495 ,  A61K31/55 ,  C07C233/80 ,  A61K31/381 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/4468 ,  C07D309/14 ,  C07C271/22 ,  C07D317/58 ,  C07D223/16 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D333/20 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D405/04 ,  C07D239/36 ,  C07D409/04 ,  C07D471/04 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D263/34 ,  C07C235/56 ,  C07D207/06 ,  C07C237/40 ,  C07D495/04 ,  C07D207/337 ,  C07D277/20 ,  C07D277/28 ,  C07D277/30 ,  C07D209/08 ,  C07D277/62 ,  C07D209/42 ,  C07D513/04 ,  C07D209/46 ,  C07D209/48 ,  C07D285/06 ,  C07D211/56 ,  C07D211/58 ,  C07D295/14 ,  C07D211/76 ,  C07D213/04 ,  C07D213/38 ,  C07D213/56 ,  C07D211/98 ,  C07D335/02 ,  C07C237/42 ,  C07C271/20 ,  C07D211/40 ,  C07D231/26 ,  C07D295/135 ,  C07D295/155

CPC classification number: C07C233/80 ,  A61K31/167 ,  A61K31/36 ,  A61K31/366 ,  A61K31/381 ,  A61K31/40 ,  A61K31/402 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/421 ,  A61K31/426 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/4468 ,  A61K31/451 ,  A61K31/495 ,  A61K31/55 ,  C07C235/56 ,  C07C237/40 ,  C07C237/42 ,  C07C271/20 ,  C07C271/22 ,  C07C2601/02 ,  C07C2601/18 ,  C07C2602/08 ,  C07D207/06 ,  C07D207/337 ,  C07D209/08 ,  C07D209/42 ,  C07D209/46 ,  C07D209/48 ,  C07D211/40 ,  C07D211/56 ,  C07D211/58 ,  C07D211/76 ,  C07D211/98 ,  C07D213/04 ,  C07D213/38 ,  C07D213/56 ,  C07D223/16 ,  C07D231/14 ,  C07D231/20 ,  C07D231/22 ,  C07D231/26 ,  C07D231/56 ,  C07D233/61 ,  C07D233/64 ,  C07D239/36 ,  C07D261/08 ,  C07D261/10 ,  C07D263/32 ,  C07D263/34 ,  C07D277/20 ,  C07D277/28 ,  C07D277/30 ,  C07D277/62 ,  C07D285/06 ,  C07D295/135 ,  C07D295/14 ,  C07D295/155 ,  C07D309/14 ,  C07D317/58 ,  C07D333/20 ,  C07D335/02 ,  C07D405/04 ,  C07D409/04 ,  C07D471/04 ,  C07D495/04 ,  C07D513/04

Abstract: The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q1, Q2, Q3 and Q4 are each a hydrogen atom or a substituent; Q1 and Q2, and Q3 and Q4, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y1, Y2 and Y3 are each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y1, and Y1 and Y2, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z1, Z2 and Z3 are each H or a substituent, or a salt thereof.

公开(公告)号：US12152027B2

公开(公告)日：2024-11-26

申请号：US17296434

申请日：2019-11-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu Hirayama ,  Yoshiteru Ito ,  Noriyuki Nii ,  Youichi Kawakita ,  Shinichi Imamura

IPC: C07D487/04 ,  C07D471/04

Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.